Disease · MONDO_0016703

anaplastic oligoastrocytoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. anaplastic oligoastrocytoma. Diseases, record MONDO_0016703. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0016703

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: anaplastic oligoastrocytoma; Open Targets
Open Targets ID: MONDO_0016703; Open Targets
Other names: WHO grade III mixed glioma, aMOA, anaplastic mixed glioma; Open Targets
NCI Thesaurus: C6959; NCI Thesaurus
Orphanet: ORPHA:251663; Orphanet
Highest stage of its drugs: Phase 3, for 3 of its 11 drugs, from ClinicalTrials.gov; Open Targets

Drugs11

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
LOMUSTINE	CHEMBL514	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
PROCARBAZINE	CHEMBL1321	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
VINCRISTINE	CHEMBL90555	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
TEMOZOLOMIDE	CHEMBL810	Small molecule	Phase 2	ClinicalTrials.gov	5	5	5	Drugs and targets
BUSULFAN	CHEMBL820	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
CARMUSTINE	CHEMBL513	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
CETUXIMAB	CHEMBL1201577	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
LEFLUNOMIDE	CHEMBL960	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
THIOTEPA	CHEMBL671	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
AXL-1717	CHEMBL283120	Small molecule	Phase 1/2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 11

See all 11 drugs

Targets28

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
BRAF	Serine/threonine-protein kinase B-raf	1	Serine/threonine-protein kinase B-raf inhibitor	Phase 1	https://conductscience.org/library/genes/673	Drugs and targets
DHODH	Dihydroorotate dehydrogenase (quinone), mitochondrial	1	Dihydroorotate dehydrogenase inhibitor	Phase 2	https://conductscience.org/library/genes/1723	Drugs and targets
EGFR	Epidermal growth factor receptor	1	Epidermal growth factor receptor erbB1 inhibitor	Phase 2	https://conductscience.org/library/genes/1956	Drugs and targets
FLT1	Vascular endothelial growth factor receptor	1	Vascular endothelial growth factor receptor inhibitor	Phase 1	https://conductscience.org/library/genes/2321	Drugs and targets
FLT3	Receptor-type tyrosine-protein kinase FLT3	1	Tyrosine-protein kinase receptor FLT3 inhibitor	Phase 1	https://conductscience.org/library/genes/2322	Drugs and targets
FLT4	Vascular endothelial growth factor receptor	1	Vascular endothelial growth factor receptor inhibitor	Phase 1	https://conductscience.org/library/genes/2324	Drugs and targets
GSR	Glutathione reductase, mitochondrial	1	Glutathione reductase inhibitor	Phase 2	https://conductscience.org/library/genes/2936	Drugs and targets
IGF1R	Insulin-like growth factor 1 receptor	1	Insulin-like growth factor I receptor inhibitor	Phase 1/2	https://conductscience.org/library/genes/3480	Drugs and targets
KDR	Vascular endothelial growth factor receptor	1	Vascular endothelial growth factor receptor inhibitor	Phase 1	https://conductscience.org/library/genes/3791	Drugs and targets
KIT	Mast/stem cell growth factor receptor Kit	1	Stem cell growth factor receptor inhibitor	Phase 1	https://conductscience.org/library/genes/3815	Drugs and targets

1 to 10 of 28

See all 28 targets

Trials9

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00588523	Intensive Chemotherapy and Autotransplantation for Patients With Newly Diagnosed Anaplastic Oligodendroglioma	Phase 2	60	2023-10-27	CNS Cancer, CNS BRAIN	BUSULFAN, TEMOZOLOMIDE, THIOTEPA	Its record names the disease	ClinicalTrials.gov
NCT01721577	Phase I/II Trial of AXL1717 in the Treatment of Recurrent Malignant Astrocytomas	Phase 1/2	10	2023-05-22	Glioblastoma, Gliosarcoma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Oligoastrocytoma, Anaplastic Ependymoma	AXL-1717	Its record names the disease	ClinicalTrials.gov
NCT00002569	Radiation Therapy With or Without Chemotherapy in Treating Patients With Anaplastic Oligodendroglioma	Phase 3	299		Brain and Central Nervous System Tumors	LOMUSTINE, PROCARBAZINE, VINCRISTINE	Its record names the disease	ClinicalTrials.gov
NCT01534845	Efficacy Study of Radiotherapy Alone Versus CCRT With Temozolomide in Grade III Gliomas Without 1p/19q Codeletion	Phase 2	90		Anaplastic Glioma of Brain, Loss of Chromosomes 1p/19q	TEMOZOLOMIDE	Its record names the disease	ClinicalTrials.gov
NCT00003176	Temozolomide and Carmustine in Treating Patients With Anaplastic Glioma	Phase 2	82		Brain and Central Nervous System Tumors	CARMUSTINE, TEMOZOLOMIDE	Open Targets' reading of its record	ClinicalTrials.gov
NCT00003775	Leflunomide in Treating Patients With Anaplastic Astrocytoma in First Relapse	Phase 2	60		Brain and Central Nervous System Tumors	LEFLUNOMIDE	Its record names the disease	ClinicalTrials.gov
NCT02800486	Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA	Phase 2	37		Glioblastoma, Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Glioma, Brain Neoplasm, Brain Cancer, Brain Tumor, Brain Tumor, Recurrent, Brain Neoplasm, Malignant	CETUXIMAB	Its record names the disease	ClinicalTrials.gov
NCT01847235	Temozolomide in Relapsed or Advanced Anaplastic Oligodendroglioma and Oligoastrocytoma: Single-arm, Phase II Trial	Phase 2	23		Anaplastic Oligodendroglioma, Anaplastic Oligoastrocytoma	TEMOZOLOMIDE	Its record names the disease	ClinicalTrials.gov
NCT00884416	Sorafenib in Newly Diagnosed High Grade Glioma	Phase 1	17		Glioblastoma, Gliosarcoma, Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma	SORAFENIB, TEMOZOLOMIDE	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials1

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial
AXL1717, 400mg Initial Dose vs AXL1717, 300mg Initial Dose: Phase I Subjects - Imaging Evidence of Response.	0 of 2	5 of 7	9	NCT01721577

Source Trial comparisons

Papers from its trials10

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
24786603	RESULT	1	PubMed
19783377	RESULT	1	PubMed
18371182	RESULT	1	PubMed
16782910	RESULT	1	PubMed
15073861	RESULT	1	PubMed
14769138	RESULT	1	PubMed
11586105	RESULT	1	PubMed
35731991	DERIVED	1	PubMed
28472509	DERIVED	1	PubMed
23071247	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0016703

GET https://conductscience.org/api/diseases/v1/MONDO_0016703/targets?page=2

API reference For AI assistants